Filing Details

Accession Number:
0001596783-23-000090
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-25 18:52:12
Reporting Period:
2023-08-23
Accepted Time:
2023-08-25 18:52:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1596783 Catalent Inc. CTLT Pharmaceutical Preparations (2834) 208737688
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1862832 Ricky Hopson C/O Catalent, Inc.
14 Schoolhouse Road
Somerset NJ 08873
Pres. Clinical Dev Supply Div No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-23 789 $0.00 21,836 No 4 A Direct
Common Stock Disposition 2023-08-24 276 $44.56 22,040 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Received upon the achievement of the fiscal 2021-23 performance-based vesting criteria set forth in certain incentive compensation held by the reporting person under the Issuer's long-term incentive plan.
  2. Includes restricted stock units.
  3. Shares sold by the reporting person through an automatic "sell to cover" transaction in order to cover tax withholding obligations in connection with the vesting of performance share units received pursuant to the Issuer's long-term incentive plan. No shares were withheld by or surrendered to the Issuer.
  4. Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $44.25 to $44.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The number of securities reported reflects the acquisition since April 12, 2023 of 480 shares of the Issuer's common stock pursuant to the Issuer's Employee Stock Purchase Plan in transactions exempt from Section 16(b).